This is preclinical work: the researchers used mouse tumor models, human immune cells, human tumor samples, and large public oncology databases. Therefore, the results cannot be interpreted as proof that montelukast is already effective in treating cancer in patients; rather, they represent a strong experimental signal that still needs to be confirmed in clinical trials.